The past week has handed BioNTech a study in contradictions. On Friday, the FDA signed off on the updated Covid-19 vaccine ...

BioNTech's colorectal cancer vaccine just collapsed in a Phase 2 trial, dragging Moderna down with it despite last week's ...

BioNTech SE maintains a Strong Buy rating, driven by robust late-stage oncology pipeline momentum and strategic partnerships.

COVID-19 vaccine formula targets the XFG variant, in line with FDA guidance to more closely match contemporary circulating variantsShipping will begin immediately to ensure rapid access to this season ...

The Food and Drug Administration has approved the latest version of Pfizer and BioNTech's COVID-19 vaccine, the companies ...

In August 2026, Pfizer and BioNTech received U.S. FDA approval for their updated COMIRNATY COVID-19 vaccine targeting the XFG ...

US pharma major Pfizer and German biotech firm BioNTech have secured US Food and Drug Administration (FDA) clearance for the ...

Biotech stocks had already been gaining ground before this week’s news. In June, the iShares Nasdaq Biotechnology ETF (IBB) ...

The 2025-2026 COVID-19 vaccine formulation targets the SARS-CoV-2 sublineage LP.8.1, in line with FDA guidance to more closely match circulating strains1 Shipping of the LP.8.1-adapted vaccine will ...

Shares of Germany-based BioNTech were down as much as 8% Friday after announcing a Phase 2 trial of autogene cevumeran would ...